PMCC PMCC

Search tips
Search criteria

Advanced
Results 1-4 (4)
 

Clipboard (0)
None

Select a Filter Below

Journals
Authors
more »
Year of Publication
Document Types
1.  Expression of prostaglandin I2 (prostacyclin) receptor in blood of migraine patients: A potential biomarker 
Background:
Migraine is the most common chronic neurological disorders that may be associated with vasodilatation. According to the role of prostaglandin I2 (prostacyclin) receptor (PTGIR) in migraine as a receptor, which acts in vasodilatation, we decided to study the changes of PTGIR expression in migraine patients in relation to a suitable control group.
Materials and Methods:
Extracted mRNA from lymphocytes of 50 cases and 50 controls was used to synthesize cDNA. Real-time polymerase chain reaction was performed, and the data were analyzed. Our results show that PTGIR mRNA expression in cases was significantly higher than the control group (P = 0.010).
Results:
In conclusion, mRNA expression of PTGIR in the blood of people with migraines could be considered as a biomarker.
Conclusion:
In addition, repression of PTGIR gene expression by methods such as using siRNA is probably suitable for therapy of migraine patients.
doi:10.4103/2277-9175.158030
PMCID: PMC4513332  PMID: 26261823
Biomarker; expression; migraine; prostaglandin I2; receptor
2.  Factor V Leiden, factor V Cambridge, factor II GA20210, and methylenetetrahydrofolate reductase in cerebral venous and sinus thrombosis: A case-control study 
Background:
Factor V G1691A (FV Leiden), FII GA20210, and methylenetetrahydrofolate reductase (MTHFR) C677T mutations are the most common genetic risk factors for thromboembolism in the Western countries. However, there is rare data in Iran about cerebral venous and sinus thrombosis (CVST) patients. The aim of this study was to evaluate the frequency of common genetic thrombophilic factors in CVST patients.
Materials and Methods:
Forty consequently CVST patients from two University Hospital in Isfahan University of Medical Sciences aged more than 15 years from January 2009 to January 2011 were recruited. In parallel, 51 healthy subjects with the same age and race from similar population selected as controls. FV Leiden, FII GA20210, MTHFR C677T, and FV Cambridge gene mutations by polymerase chain reaction technique were evaluated in case and control groups.
Results:
FV Leiden, FII GA20210, and FV Cambridge gene mutations had very low prevalence in both case (5%, 2%, 0%) and control (2.5%, 0%, 0%) and were not found any significant difference between groups. MTHFR C677T mutations was in 22 (55%) of patients in case group and 18 (35.5%) of control group (P = 0.09).
Conclusion:
This study showed that the prevalence of FV Leiden, FII GA20210, and FV Cambridge were low. Laboratory investigations of these mutations as a routine test for all patients with CVST may not be cost benefit.
doi:10.4103/1735-1995.165956
PMCID: PMC4621649  PMID: 26600830
Cerebral venous and sinus thrombosis; factor II GA20210; factor V Cambridge; factor V Leiden; methylenetetrahydrofolate reductase
3.  Factor V Leiden does not have a role in cryptogenic ischemic stroke among Iranian young adults 
Background:
Different risk factors have been suggested for ischemic stroke in young adults. In a group of these patients despite of extensive diagnostic work-up, the primary cause remains unknown. Coagulation tendency is accounted as a possible cause in these patients. Previous studies on factor V Leiden (FVL) as the main cause of inherited thrombophilia for clarifying the role of FVL in stroke have resulted in controversial findings. The current study investigates the role of this factor in ischemic stroke among Iranians.
Materials and Methods:
This case-control study was performed between September 2007 and December 2008 in Isfahan, Iran. The case group comprised of 22 patients of which 15 were males and 7 were females with age range of ≤50 years, diagnosed as ischemic stroke without classic risk factors and the control group consisted of 54 healthy young adults. After filling consent form, venous blood samples were obtained and sent to the laboratory for genetic examination.
Results:
No FVL mutation was found in the case group. There was one carrier of the mutation as heterozygous in the control group (relative frequency = 1.85%).
Conclusions:
Based on our study, FVL might not be considered as an independent risk factor for ischemic stroke in Iranian individuals who are not suffering from other risk factors of ischemic stroke.
doi:10.4103/2277-9175.127993
PMCID: PMC3988598  PMID: 24761388
Cryptogenic; factor V Leiden; stroke; young adults
4.  The impact of prothrombin (G20210A) gene mutation on stroke in youths 
ARYA Atherosclerosis  2012;8(1):9-11.
BACKGROUND
Stroke in young adults is a known but abnormal disease. Several recent studies have discussed the correlation between existence of coagulation factors such as V Leiden and prothrombin mutation (G20210A) as risk factors for incidence of stroke. The present study investigated the frequency of prothrombin gene mutation and its impact on incidence of ischemic stroke in Iranian youth.
METHODS
This was a case-control study using convenient sampling method on seventy six 18 to 50-year-old people provided that they did not have classical risk factors for stroke. Case group comprised 22 patients with ischemic stroke (15 males and 7 females). Fifty four healthy people (17 males and 37 females) were selected as the control group. Participants in both groups were recruited within 26 months (23.9.2007 to 21.11.2009) in Al-Zahra Hospital, Isfahan, Iran.
RESULTS
Prothrombin was not found in any of the studied patients. Heterozygous mutation was observed in one of the samples of the control group (1.85%).
CONCLUSION
Despite the known effect of prothrombin gene mutation on incidence of venous thrombosis, it does not seem this factor, as an independent factor, can be considered as a risk factor to create ischemic stroke in people who do not have other risk factor.
PMCID: PMC3448394  PMID: 23056093
Prothrombin Mutation; Stroke; Youth; Risk Factor

Results 1-4 (4)